ClinicalTrials.gg
CompletedNCT01081574Updated Sep 26, 2012

Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)

A Phase 1/2 interventional study of Bilastine in Allergic Rhinoconjunctivitis and Chronic Urticaria, sponsored by Faes Farma, S.A.. Completed at 7 sites in 3 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-09-26.

Sponsored by Faes Farma, S.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Chronic Urticaria with a site in Germany — 5 open to participants now, 13 under way, 6 of them phase 3. Chronic Urticaria · Germany.

Enrollment
44th of 49
36 · median 136
Started
2010
the only one that year
Phase 1/2
3 of 55
none open now
Registered
5th of 55
by date

Among the 55 studies in Chronic Urticaria with a site in Germany, this one is the 44th largest by enrollment of the 49 interventional ones that give a count, is the only one that started in 2010, is one of 3 in phase 1/2, and was the 5th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

5 of the 55 studies in Chronic Urticaria with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Chronic Urticaria with a site in Germany, or all of them as a file.
02

Study summary

The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population subset.

Read the detailed description

The objective of this study is to assess the pharmacokinetics of bilastine in children (aged 2 to \<12 years) with allergic rhinoconjunctivitis (seasonal allergic rhinitis [SAR] and/or perennial allergic rhinitis [PAR]) or chronic urticaria (CU) in order to ascertain that the systemic exposure attained with a dose of 10 mg/QD or lower is comparable to that achieved in adults and adolescents administered with a dose of 20 mg/QD.

Additional objectives are to describe the safety and tolerability of a repeated administration of bilastine in children with AR or CU.

03

Conditions studied

  • Allergic Rhinoconjunctivitis
  • Chronic Urticaria

Keywords

  • Allergic Rhinitis
  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Urticaria
  • Chronic Idiopathic Urticaria
  • Allergy
  • Sneezing
  • Nasal Itching
  • Rhinorrhea
  • Nasal Congestion
  • Wheals
  • Hives
  • Skin itching
  • Flare
  • Erythema
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Either sex aged from ≥ 2 to \< 12 years of age. Female subjects must not be of child bearing potential.
  2. Height and weight within a majority range (e.g., 25th through 75th percentile) of the subject's age and sex as provided in national tables.
  3. Documented history of SAR/PAR or CU at the time of inclusion. Subjects must be symptomatic at screening as judged by the investigator.
  4. A documented positive skin prick test or IgE test (RAST) for at least one seasonal or perennial allergen in children with AR obtained within the 12 months prior to inclusion.
  5. Excepting AR or CU, judged to be in general good health based on medical history, physical examination and clinical laboratory tests, with a duration on the recorded at screening within the normal range (≤ 440 msec).
  6. Written signed by the legal representative of the minor (his/her parent(s) or a person legally appointed if different from parent(s)) and, where applicable, assent signed by the child, according to local regulations.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects of . If menarche occurs after study enrolment and during the dosing period, the subject should be discontinued from the treatment and followed up for safety as per protocol. Occurrence of menarche in the course of the study should always be documented.
  2. Intake of another medication in another clinical study within 30 days prior to the first study drug intake.
  3. abnormalities as judged by the investigator (e.g., Wolff-Parkinson-White [WPW] syndrome, long syndrome).
  4. Known allergy/ to the study drug or its inactive ingredients.
  5. Any clinical conditions or circumstances that in the opinion of the investigator would make the subject unsuitable for the study (e.g., hepatic impairment, renal impairment, mental impairment, cardiac disease).
  6. Subjects with known positive surface antigen (Hbs Ag), or antibody or who are known to be (HIV) positive. No testing will be required for this study.
  7. Subjects who are expected to take during the study period or have taken any of the following medications prior to inclusion in the study and have not complied with the specified wash out period of 7 days unless otherwise noted:

    • Oral .
    • Oral antihistamines: loratadine, desloratadine, and fexofenadine.
    • Anti-leukotrienes
    • Amoxicillin, benzylpenicillin, and macrolide antibiotics and imidazolic antifungals (systemic)
    • Omeprazol
    • Aspirin, ibuprofen
    • Carbamazepine
    • St. John's Wort (15 days)
  8. Hypersensitivity to H1 antihistamines or benzimidazoles.
  9. Ingestion of citrus fruits and cranberries or any fruit juice or any other well known PgP or organic anion transporter polypeptide (OATP) inhibitor, inducer, or substrate (see Appendix C) within 7 days prior to first dose of study medication.
  10. Mentally disabled minors or Minors who by official order have been institutionalised (e.g., in orphanages) must be excluded from participation.
  11. Minors who explicitly refuse to take part in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    10 mg Bilastine once daily for 7 days

    10 mg Bilastine dispersible oral tablet

    Drug: Bilastine

Interventions

  • 10 mg/qd/ 7 days.Oral dispersible tablets

    Also known as: Bilaxten

06

What researchers measure

Primary outcomes

  1. The primary objective is to assess the pharmacokinetics of bilastine in children (aged 2 to <12 years) with allergic rhinoconjunctivitis (seasonal allergic rhinitis and/or perennial allergic rhinitis [SAR/PAR]) or chronic urticaria (CU)

    Determination of plasma concentrations versus time (between 1 and 6 samples per subject at various time intervals after dosing according to an optimised sampling protocol) in order to perform a population pharmacokinetic analysis. For Group A, samples of venous blood will be just prior to dose administration, and at 0.25, 0.5, 0.8, 1.0, 1.2, 1.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, and 24.0 hours after dose administration. For Group B samples of venous blood will be just prior to dose administration, and at 0.25, 0.5, 1.0, 1.5, 3.0, 6.0, 8.0, 10.0, and 12.0 hours after dose administration.

    Time frame: 1 day (visit 3, Day 7)

Secondary outcomes

  1. The secondary objectives are to describe the safety and tolerability of a repeated administration of bilastine in the aforementioned paediatric subset with allergic rhinoconjunctivitis (SAR/PAR) or chronic urticaria (CU).

    Safety will be assessed during the study by monitoring adverse events (AEs), clinical laboratory test results (urinalysis, blood chemistry, and haematology), vital signs (including blood pressure, respiration, temperature, and heart rate, supine and standing), electrocardiogram (ECG) results, and abnormal findings upon physical examination.

    Time frame: 5 weeks

07

Study locations

7 sites
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Princess Margaret Hospital for Children
    Subiaco, Western Australia 6840, Australia
  • Charité - Universitätsmedizin. Campus Virchow-Klinikum. Klinik für Pädiatrie mit Schwerpunkt Pneumologie/Immunologie
    Berlin, 13353, Germany
  • Klinikum der Johann-Wolfgang-Goethe-Universität Frankfurt
    Franfurt, 60590, Germany
  • Universitäts-Hautklinik
    Kiel, 24105, Germany
  • Karolinska University Hospital. Astrid Lindgren's Hospital
    Stockholm, 17176, Sweden
  • Children's Hospital at Uppsala University Hospital
    Uppsala, 751 85, Sweden
08

References and documents

Publications

  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodriguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48(8):543-54. doi: 10.2165/11317180-000000000-00000. PubMed 19705924 ↗
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antepara I, Jauregui I, Valiente R; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010 Apr;65(4):516-28. doi: 10.1111/j.1398-9995.2009.02217.x. Epub 2009 Oct 23. PubMed 19860762 ↗
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010 May;59(5):391-8. doi: 10.1007/s00011-009-0117-4. Epub 2009 Nov 27. PubMed 19943178 ↗
  • Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009 Sep;39(9):1338-47. doi: 10.1111/j.1365-2222.2009.03257.x. Epub 2009 May 4. PubMed 19438584 ↗
  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x. PubMed 19132976 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 5, 2010
Start
Jan 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Sep 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01081574
Lead sponsor
Faes Farma, S.A.
Responsible party
Sponsor
First posted
Mar 5, 2010
Start date
Jan 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Sep 26, 2012

Study contacts

Ulrich Wahn, Prof. Dr.
principal investigator · International Coordinating Investigator. Charité - Universitätsmedizin Berlin (Germany)
Regina Föster-Holst, Prof. Dr.
principal investigator · Universitäts-Hautklinik Kiel (Germany)
Belén Sádaba, Dr.
principal investigator · Clínica Universitaria de Navarra (Spain)
Gunilla Hedlin, Prof. Dr.
principal investigator · Karolinska University Hospital
Stefan Zielen, Prof. Dr.
principal investigator · J.W. Goethe-Universität Frankfurt (Germany)
Lennart Nordvall, Prof. Dr
principal investigator · Children's Hospital at Uppsala University Hospital (Sweden)
Peter Le Souef, Prof. Dr.
principal investigator · Princess Margaret Hospital for Children (Australia)
Noel E Cranswick, Prof. Dr.
principal investigator · Royal Children's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion